Background: Ticagrelor, a reversible P2Y12 inhibitor, is a mainstay of antiplatelet strategy in patients with
Introduction
Antiplatelet therapy with P2Y12 inhibitors is a mainstay strategy for the management of acute coronary syndrome (ACS) patients. Ticagrelor, novel and reversible P2Y12 inhibitor, is recommended as a class I therapy for 12 months after an ACS event by the European Society of Cardiology and the American College of Cardiology/American Heart Association guideline committees [1] [2] [3] . The optimal antiplatelet effect prevents from thrombotic complications, including devastating in consequences stent thrombosis that drives cardiovascular mortality in the early stage post percutaneous coronary intervention (PCI) [4] [5] [6] [7] . The potency of antithrombotic strategy with novel P2Y12 inhibitor, ticargelor, as compared to its irreversible counterpart clopidogrel, is well established [8] [9] [10] . In large randomized controlled trial (RCT) ticagrelor (90 mg or 60 mg, twice daily) in combination with aspirin significantly reduced the risk of cardiovascular death, myocardial infarction (MI), or stroke as compared with clopidogrel in patients who had prior MI 1-3 years earlier [11] . Bleeding and respiratory adverse events, however, were more frequently observed with ticagrelor use.
One of the reasons of ineffectiveness of antiplatelet therapy originates from low adherence and discontinuation of the therapy due to adverse events [12] [13] [14] [15] [16] [17] . Dyspnea is a relatively frequent adverse event ob-served during ticagrelor therapy, and while it is usually reported as "mild" or "moderate" in intensity among patients experiencing it, it remains an overt reason for discontinuation of the assigned treatment [18] . In the secondary analysis of the PEGASUS-TIMI 54 Trial the rate of discontinuation due to an adverse event was the highest in the treatment arm receiving 90 mg of ticagrelor (19%), followed by the treatment arm receiving 60 mg of ticagrelor (16%), both of which were significantly higher than that in the placebo arm (9%), with the differences most marked within the first year from randomization [19] . A dose-dependent relative increase of both dyspnea and dyspnea requiring discontinuation was present, however, the discontinuation rate resulting from dyspnea among those subjects, who reported dyspnea, was 5-flod higher than observed in the PLATO trial. Interestingly, discontinuation due to dyspnea (6.2% ticagrelor 90 mg bid vs 4.3% ticagrelor 60 mg bid vs 0.7% placebo) had the same prevalence as the disocntinuation due to bleeding (6.5% ticagrelor 90 mg bid vs 5.1% ticagrelor 60 mg bid vs 1.2% placebo). The increased risk of bleeding is on the other side of spectrum of thrombotic milieu and is inevitable in successful antithrombotic management; dyspnea, however, remains an adverse event with a high potential of prevention [14] . Ticagrelor-induced dyspnea exerts generally no effort on the patient's activities of daily life and can be resolved quickly, as it does not influence the patient's cardiac nor pulmonary function. Taking together not sufficient awareness of the recognition and management of ticagrelor-related dyspnea, especially among elderly ACS patients treated with several drugs, there exists a global underestimation and mismanagement of this adverse event [20] . For a proper management of patients complaining of dyspnea when taking ticagrelor, all clinically plausible causes of dyspnea must be considered before attributing it to medication itself [21] . Episodes of dyspnea tend to occur during first days after the initiation of the therapy [18] . Dyspnea may have devastating effects when leading to treatment discontinuation, especially in the case of frail population as ACS patients. In the first multicenter observational prospective study to investigate rate of ticagrelor-related dyspnea and its impact on daily life in patients in their first month post PCI, ticagrelor was withdrawn in 16.7% patients during the 1 st month of follow-up, with ticagrelor-related dyspnea at the rate of 55.6% of all withdrawal reasons [22] . To provide further optimization of the antiplatelet strategies it is mandatory to avoid discontinuation due to a preventable adverse event.
A number of potential mechanisms could cause ticagrelor-induced dyspnea. It has been hypothesized that the sensation of dyspnea is related to reversibility of the P2Y12 inhibiting agent origins from increased levels of adenosine, which cellural reuptake is impaired [23] .
Pulmonary vagal C fibres are stimulated by increased adenosine levels through the A 1 R and A 2A R receptors on vagal sensory C fibers, which mediate the sensation of dyspnea. The increase in serum adenosine is higher with reversible (i.e. ticagrelor) rather than irreversible P2Y12 inhibitors (clopidogrel) [24] . Therefore, potential treatment options for ticagrelor-associated dyspnea may include adenosine antagonism, such as aminophylline or theophylline. The cases of successful reversal of ticagrelor-induced dyspnea have been described in literature [25] . Their role is still not yet fully addressed in a large clinical study. In a promising randomized trial TROCADERO (TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr) the primary objective was to assess the efficacy of caffeine in reducing symptoms of ticagrelor-induced dyspnea, measured by the visual analog scale area under the curve (VAS AUC), in patients after an ACS [26] . However, out of 514 subjects who participated in the questionnaire survey, only a small number of patients experienced dyspnea that required an intervention and were randomized to one of the strategies: 13 to caffeine, and 10 to placebo. In this context, dyspnea and treatment to evelate its symptoms were not prospectively assessed in a large study with a use of standardized tool, thus, its prevalence and severity is not well established.
In the PREDATOR program, we aim for the first time to 1) prospectively assess dyspnea rate with a loading dose of reversible P2Y12 inhibitor, ticagrelor, 2) analyze a potential of theophylline to elevate symptoms of ticagrelor-induced dyspnea, 3) prospectively assess dyspnea and adverse events rate with a maintenance dose of P2Y12 inhibitors. All evaluations will be conducted using standardized metrics for dyspnea quantification.
Methods

Program design and objectives
The PREvalence of DyspneA in patients treated with TicagrelOR (PREDATOR) is an international, multicenter program consisting of two trials preceded by pilot studies (Figure 1) . The inclusion and exclusion criteria for both PREDATOR Loading Dose (LD) Study and PREDATOR Maintenance Dose (MD) Study are presented in Table 1 . The same criteria will apply to the pilot studies. The main objective of the program is to prospectively and quantitatively assess, with the use of a standardized score, prevalence of dyspnea with ticargelor and a potential of theophylline administration on dyspnea cessation among ACS and stable CAD patients. The study will be conducted in accordance with the principles contained in the Dec-www.journals.viamedica.pl/medical_research_journal • history of coagulation disorders • history of moderate or severe hepatic impairment • history of major surgery or severe trauma (within 3 months)
• patient required dialysis • manifest infection or inflammatory state
• respiratory failure • current therapy with strong CYP3A inhibitors or strong CYP3A inducers laration of Helsinki, and every study site will receive an approval from the Local Ethics Committee. Each patient will provide a written informed consent to participate in the study.
Statistical design and analysis
Since the rate of dyspnea with ticagrelor use varies in definitions and rates across previously published literature, we decided to perform preceding pilot studies to estimate the sample size.
PREDATOR LD
The PREDATOR LD is a double-blind, placebo-controlled, randomized trial in low-to-high risk acute coronary syndromes without ST-segment elevation (NSTE-ACS) and stable coronary disease designated to undergo invasive treatment. The primary objective of the study is to evaluate the occurrence of dyspnea after 180 mg ticagrelor loading dose, with following secondary objective of assessing relief of dyspnea by theophylline administration. Patients will undergo two stages of randomization -first randomization to 180 mg ticagrelor LD vs. placebo followed by a switch of therapy after 2 hours in patients without dyspnea, and second randomization to theophylline p.o. (loading dose 5 mg/kg, maintenance dose 100 mg tid) vs. placebo p.o. of only patients with dyspnea in 1st randomization stage (Figure 2) . The study follow-up will be stratified to three durations, driven by randomization: 1) 1 st follow-up, within 2 hours after first randomization (patients with dyspnea directly undergo second randomization, while patients without dyspnea by the end of follow-up have the allocated therapy switched), 2) 2 nd follow-up, within 2 hours after the 1 st follow-up, up to 4 hours after first randomization (patients with dyspnea undergo second randomization, while patients without dyspnea undergo coronary angiography/PCI), 3) 3 rd follow-up, within 1 hour after second randomization, and up to 5 hours after first randomization (all patients undergo coronary angiography/PCI, while for patients in whom dyspnea have occurred at first follow-up period the study treatment will be unblinded after termination of the protocol and before PCI; patients in placebo arm 10 Maximal will unblindly receive ticagrelor LD). Dyspnea, as well as the relief from it, will be quantified with the Modified Borg Dyspnoea Score ( Table 2 ). The exact number of study population will be determined based on the PREDATOR LD pilot study including 200 patients.
PREDATOR MD
The PREDATOR MD is a double-blind, placebo-controlled, cross-over, randomized trial conducted in stable coronary artery disease (CAD) patients 1 year after PCI for ACS. Enrolled patients will be randomized to one of four antiplatelet treatment regimens (ticagrelor 2x90 mg or ticagrelor 2x60 mg or ticagrelor 2x45 mg or clopidogrel 75 mg [morning] + placebo [evening]) or placebo (1:1:1:1:1 ratio), and will be assessed for dyspnea at the day 7 of the allocated therapy. On the same day all patients will undergo a switch of treatment and will be reassessed for dyspnea at day 14. The primary objective of the study is to evaluate the occurrence of dyspnea with different maintenance dose of antiplatelet treatment regimens. Dyspnea will be quantified with the Modified Borg Dyspnoea Score. The secondary endpoints of this study, evaluating the safety of P2Y12 inhibiting therapy, include major bleedings according to the Thrombolysis In Myocardial Infarction (TIMI) criteria, minor bleedings according to TIMI criteria, clinically relevant bradycardia, level of serum uric acid, neutrophil count, overall premature discontinuation of the study drug and discontinuation of the study drug due to dyspnoe. Discontinuation is defined as study drug cessation following medical contact. The exact number of study population will be determined based on the PREDATOR MD pilot study including 400 patients.
study organization
The executive committee is responsible for the overall design, conduct, and supervision of the study, 
conclusions
The PREDATOR program includes phase III and IV, multicenter, randomized, double-blind, placebo-controlled clinical trials that assesses the prevalence and treatment of ticagrelor-induced dyspnea in CAD/ACS patients. Those trials will provide important information regarding the impact of ticagrelor loading and maintenance dose on the occurrence and severity of dyspnea, prospectively assessed by a standardized score. A disclosure of such information could provide medical practitioners with more effective tools preventing from consequences of therapy discontinuation due to mild adverse events.
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